Back to Search
GERARD SANACORA, M.D., PH.D.
Psychiatry Physician
NPI: 1992779151IndividualAccepts Medicare
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
035342(CT)
Education
STATE UNIVERSITY OF NEW YORK AT STONY BROOK, SCHOOL OF MEDICINE
Class of 1994
Research & Publications (20)
Reviewing medications for bipolar disorder: understanding the mechanisms of action.
PMID 19222977·J Clin Psychiatry·2009
6-review
New understanding of mechanisms of action of bipolar medications.
PMID 19265637·J Clin Psychiatry·2008
6-review
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
PMID 18425072·Nat Rev Drug Discov·2008
6-review
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
PMID 17141740·Biol Psychiatry·2007
3-trial
Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy.
PMID 16139814·Biol Psychiatry·2006
4-observational
Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
PMID 15010697·Neuropsychopharmacology·2004
3-trial
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.
PMID 15237082·Arch Gen Psychiatry·2004
4-observational
Increased cortical GABA concentrations in depressed patients receiving ECT.
PMID 12611844·Am J Psychiatry·2003
4-observational
Clinical studies implementing glutamate neurotransmission in mood disorders.
PMID 14684453·Ann N Y Acad Sci·2003
6-review
Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors.
PMID 11925309·Am J Psychiatry·2002
8-other
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
PMID 18825147·Mol Psychiatry·2010
7-preclinical
Targeting glial physiology and glutamate cycling in the treatment of depression.
PMID 19376090·Biochem Pharmacol·2009
7-preclinical
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
PMID 19460458·Drug Discov Today·2009
6-review
Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus.
PMID 18628780·J Cereb Blood Flow Metab·2008
7-preclinical
It is time to take a stand for medical research and against terrorism targeting medical scientists.
PMID 18371494·Biol Psychiatry·2008
7-preclinical
Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.
PMID 18571629·Biol Psychiatry·2008
1-meta
The NMDA receptor as a therapeutic target in major depressive disorder.
PMID 17430148·CNS Neurol Disord Drug Targets·2007
6-review
GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.
PMID 17430150·CNS Neurol Disord Drug Targets·2007
6-review
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
PMID 16860779·Biol Psychiatry·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 34 PARK ST, 3RD FLOOR, CNRU
NEW HAVEN, CT 06519 - Phone
- (203) 974-7560
Quick Facts
- NPI
- 1992779151
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile